NOT MEDICAL ADVICE

DSIP

Estimated Market Price
$79.99 $94.99
Based on verified supplier pricing for research-grade compounds
Naturally occurring nonapeptide first isolated from cerebral venous blood. Studied for sleep architecture modulation, circadian rhythm regulation, and stress-response pathways.
How it works

Promotes deep, restorative slow-wave sleep by modulating neuroendocrine signaling. Also lowers cortisol and has stress-protective properties, helping the body recover during rest.

Recovery & Longevity

What to Expect
Night 1–3 Faster sleep onset; initial delta-wave promotion noticeable. Falling asleep noticeably faster; less racing thoughts.
Week 1 Deeper slow-wave sleep; morning cortisol levels normalizing. Sleep feels deeper; waking up genuinely refreshed.
Week 2 Sleep architecture restructured; more restorative sleep cycles. Morning grogginess gone; energy consistent through the day.
Week 3–4 Peak sleep quality; stress resilience and recovery optimized. Sleep quality transformed; stress feels more manageable.

Verified Suppliers

For research purposes only. These suppliers have been independently verified by PepSpace. We do not process sales directly.

PepSpace is not affiliated with any listed supplier
Protocol & Dosage
Typical Dosage 100–300 mcg SC or intranasal before bed
Administration Intravenous, Subcutaneous injection, Intranasal
Schedule Once nightly, 30 min before sleep
Protocol Duration 2–4 weeks
Half-Life ~7 minutes
Side Effects & Safety
Tolerability Profile Mild

Generally well tolerated; side effects are mild and transient

Common Side Effects

  • Mild morning grogginesssome users
  • Vivid or unusual dreamssome users

Less Common

  • Daytime drowsiness (dose-dependent)occasional
  • Headacheoccasional
  • Injection site rednessoccasional
  • Mild GI discomfortoccasional

Discontinue If

  • Severe daytime sedation or cognitive impairment
  • Worsening insomnia or sleep disruption (paradoxical)
  • Mood changes or emerging depression

Contraindications

  • Pregnancy or breastfeeding
  • Concurrent use of sedatives or opioids
  • Severe depression or suicidal ideation

Data note: Extremely short half-life (~7 min). Side effects are mild and dose-dependent. No dependency or withdrawal reported.

Always consult a qualified healthcare professional before use. This information is for research reference only and does not constitute medical advice.

Ask about DSIP
Send us a message

Call us
+1 (518) 327-4392
Business hours
Monday – Friday 9:00 AM – 6:00 PM EST
Saturday 10:00 AM – 2:00 PM EST
Sunday Closed

You can also reach us via or .

How to Apply

1

Gather

Peptide vial, BAC water, alcohol swabs, insulin syringe

2

Sanitize

Wipe tops of both vials with alcohol swabs

3

Draw

Pull 1–2 mL of BAC water into syringe

4

Add Water

Release water slowly along vial wall, not directly on powder

5

Swirl

Roll between palms until dissolved. Never shake.

6

Store

Refrigerate 2–8°C, use within 30 days

Frequently Asked Questions

Yes. Bacteriostatic water (BAC water) is required to reconstitute lyophilized (freeze-dried) peptides. It contains 0.9% benzyl alcohol which prevents bacterial growth, keeping your reconstituted peptide safe for multiple uses over up to 30 days.

Unreconstituted: store at -20°C (freezer) for long-term, or 2–8°C (fridge) for short-term. After reconstitution: always refrigerate at 2–8°C and use within 30 days. Keep away from direct sunlight.

Results vary by individual and protocol. In research settings, measurable effects are typically observed within 1–4 weeks depending on the specific peptide, dosage, and application. Consult a qualified professional for guidance.

Verified suppliers typically include a full third-party COA verifying purity (99%+), identity, and sterility. We recommend only sourcing from vendors that provide batch-specific testing data.

We list verified suppliers above that have been independently reviewed for product quality, testing transparency, and shipping reliability. Always verify COA data before sourcing.

Compound Profile

Scientific data & classification for DSIP

Also Known As Delta Sleep-Inducing Peptide, DSIP
Classification Nonapeptide · Sleep / Neuromodulator
Sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
Molecular Formula C₃₅H₄₈N₁₀O₁₅
Molecular Weight 848.81 Da
CAS Number 62568-57-4
Half-Life ~7 minutes
Origin Isolated from rabbit cerebral venous blood during slow-wave sleep
Administration Intravenous, Subcutaneous injection, Intranasal
Status Research compound
Mechanism of Action Promotes deep, restorative slow-wave sleep by modulating neuroendocrine signaling. Also lowers cortisol and has stress-protective properties, helping the body recover during rest.
Research Overview Delta sleep-inducing peptide (DSIP) is a nonapeptide first isolated in 1977 from the cerebral venous blood of rabbits during electrically induced slow-wave sleep by a research team led by G.A. Schoenenberger in Basel, Switzerland. The peptide was identified through an elegant cross-circulation experiment - blood from sleeping donor rabbits was infused into awake recipient animals, inducing characteristic delta-wave EEG patterns associated with deep, restorative sleep. DSIP has the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, and despite its seemingly simple structure and extremely short plasma half-life of approximately 7 minutes, it exerts remarkably long-lasting effects on sleep architecture that persist for hours after administration. This paradox between pharmacokinetics and pharmacodynamics has been partially explained by studies suggesting that DSIP acts as a modulatory signal peptide that triggers downstream cascading changes in neurotransmitter systems rather than maintaining a direct receptor-mediated effect. The peptide's mechanism of action remains incompletely understood despite four decades of research - it appears to modulate multiple neuroendocrine systems including serotonergic, dopaminergic, and opioidergic pathways. DSIP has been shown to reduce cortisol levels, stimulate luteinizing hormone release, modify pain perception through interactions with the endogenous opioid system, and provide cytoprotective effects against oxidative stress. Clinical trials conducted primarily in Europe during the 1980s and 1990s demonstrated improvements in sleep quality and latency in patients with chronic insomnia, with the notable advantage of maintaining normal sleep architecture (including REM sleep proportions) rather than disrupting it as benzodiazepines do. The peptide also showed promise in substance withdrawal protocols, reducing withdrawal symptoms in both alcohol and opioid dependence models. Despite these intriguing properties, DSIP has not achieved regulatory approval in any major market, partly due to the difficulty of identifying a specific receptor target and the challenges of developing peptide-based sleep medications in an era dominated by small-molecule pharmacology.

Citations

Published findings on DSIP from peer-reviewed journals.

Research Assistant
Hey, I'm the PepSpace research assistant. Ask me anything about peptides and I'll do my best to help.